US FDA to reconsider decision barring compounded versions of Lilly weight loss drug

 The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from selling their own versions of Eli Lilly's LLY.N blockbuster weight loss and diabetes drugs.

The agency said in a court filing it would allow compounding pharmacies and facilities to continue providing the drugs for now while it reviews whether there is a shortage of their active ingredient.

https://www.xm.com/research/markets/allNews/reuters/fda-to-reconsider-decision-barring-compounded-versions-of-lilly-weight-loss-drug-53944065